Helping those with celiac disease tolerate gluten: ImmusanT raises $12M
So far, the only treatment available for celiac disease is a gluten-free diet. Cambridge biotech ImmusanT aims to reprogram the immune system of a person with celiac disease so they can tolerate gluten. ImmusanT just raised $12 million in a Series B round for its Nexvax2 drug and diagnostic for celiac disease. The dollars will go […]